Protein restriction cycles reduce IGF-1 and phosphorylated Tau, and improve behavioral performance in an Alzheimer's disease mouse model

被引:62
|
作者
Parrella, Edoardo [1 ,2 ]
Maxim, Tom [1 ,2 ]
Maialetti, Francesca [3 ]
Zhang, Lu [1 ,2 ]
Wan, Junxiang [1 ,2 ]
Wei, Min [1 ,2 ]
Cohen, Pinchas [1 ,2 ]
Fontana, Luigi [4 ,5 ,6 ]
Longo, Valter D. [1 ,2 ]
机构
[1] Univ So Calif, Longev Inst, Davis Sch Gerontol, Los Angeles, CA 90089 USA
[2] Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA
[3] Ist Super Sanita, Div Nutr & Aging, I-00161 Rome, Italy
[4] Washington Univ, Div Geriatr & Nutr Sci, St Louis, MO USA
[5] Univ Salerno, Sch Med, Dept Med, I-84100 Salerno, Italy
[6] CEINGE Biotecnol Avanzate, Naples, Italy
关键词
aging; alzheimer; IGF-1; IGFBP-1; protein restriction; tau; GROWTH-FACTOR-I; AMES DWARF MICE; CALORIC RESTRICTION; NUTRITIONAL REGULATION; TRANSGENIC MODEL; KNOCKOUT MICE; LIFE-SPAN; BRAIN; HORMONE; SERUM;
D O I
10.1111/acel.12049
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In laboratory animals, calorie restriction (CR) protects against aging, oxidative stress, and neurodegenerative pathologies. Reduced levels of growth hormone and IGF-1, which mediate some of the protective effects of CR, can also extend longevity and/or protect against age-related diseases in rodents and humans. However, severely restricted diets are difficult to maintain and are associated with chronically low weight and other major side effects. Here we show that 4months of periodic protein restriction cycles (PRCs) with supplementation of nonessential amino acids in mice already displaying significant cognitive impairment and Alzheimer's disease (AD)-like pathology reduced circulating IGF-1 levels by 3070% and caused an 8-fold increase in IGFBP-1. Whereas PRCs did not affect the levels of amyloid (A), they decreased tau phosphorylation in the hippocampus and alleviated the age-dependent impairment in cognitive performance. These results indicate that periodic protein restriction cycles without CR can promote changes in circulating growth factors and tau phosphorylation associated with protection against age-related neuropathologies.
引用
收藏
页码:257 / 268
页数:12
相关论文
共 50 条
  • [21] Protein calorie restriction affects nonhepatic IGF-1 production and the lymphoid system: Studies using the liver-specific IGF-1 gene-deleted mouse model
    Naranjo, WM
    Yakar, S
    Sanchez-Gomez, M
    Perez, AU
    Setser, J
    LeRoith, D
    ENDOCRINOLOGY, 2002, 143 (06) : 2233 - 2241
  • [22] Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies
    Pires, Geoffrey
    McElligott, Sacha
    Drusinsky, Shiron
    Halliday, Glenda
    Potier, Marie-Claude
    Wisniewski, Thomas
    Drummond, Eleanor
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2019, 7 (01)
  • [23] Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer’s disease and not in other tauopathies
    Geoffrey Pires
    Sacha McElligott
    Shiron Drusinsky
    Glenda Halliday
    Marie-Claude Potier
    Thomas Wisniewski
    Eleanor Drummond
    Acta Neuropathologica Communications, 7
  • [24] Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease
    Schönknecht, P
    Pantel, J
    Hunt, A
    Volkmann, M
    Buerger, K
    Hampel, H
    Schröder, J
    NEUROSCIENCE LETTERS, 2003, 339 (02) : 172 - 174
  • [25] CSF tau phosphorylated at threonine 231, total tau and neuronal thread protein in the diagnosis of Alzheimer's disease
    Hampel, H
    Bürger, K
    Zinkowski, R
    Teipel, SJ
    Kohnken, R
    Kerkman, D
    DeBernardis, J
    Kahle, P
    Rapoport, SI
    Sunderland, T
    Arai, H
    Tapiola, T
    Hoffmann-Kiefer, K
    Andreasen, N
    Blennow, K
    Möller, HJ
    Davies, P
    EUROPEAN PSYCHIATRY, 2002, 17 : 77S - 77S
  • [26] Donepezil May Reduce Insulin-Like Growth Factor-1 (IGF-1) Levels in Alzheimer's disease
    Ala, Tom
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2016, 15 (01) : 108 - 112
  • [27] Advances in the development of biomarkers for Alzheimer's disease:: from CSF total tau and Aβ1-42 proteins to phosphorylated tau protein
    Hampel, H
    Goernitz, A
    Buerger, K
    BRAIN RESEARCH BULLETIN, 2003, 61 (03) : 243 - 253
  • [28] Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease
    Yang, Che-Chuan
    Chiu, Ming-Jang
    Chen, Ta-Fu
    Chang, Hui-Ling
    Liu, Bing-Hsien
    Yang, Shieh-Yueh
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 61 (04) : 1323 - 1332
  • [29] Induction and spreading of tau pathology in a mouse model of Alzheimer's disease
    Clavaguera, Florence
    Goedert, Michel
    ToInay, Markus
    M S-MEDECINE SCIENCES, 2010, 26 (02): : 121 - 124
  • [30] Bin1 antibody lowers the expression of phosphorylated Tau in Alzheimer's disease
    Thomas, Sunil
    Hoxha, Kevther
    Tran, Allison
    Prendergast, George C.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (10) : 18320 - 18331